| MFS (n = 62) | p Value | |||
| Group 1 | Group 2 | Group 3 | ||
| (n = 32) | (n = 26) | (n = 4) | ||
| Age; mean (95% CI), years | 45.3 (39.8–50.8) | 43.7 (37.4–50.0) | 46.5 (33.4–59.7) | 0.898 |
| Gender (male/female); n | 24/8 | 15/11 | 2/2 | 0.304 |
| Antecedent infection; n (%) | ||||
| Respiratory | 22 (69) | 24 (92) | 3 (75) | 0.071 |
| Gastrointestinal | 7 (22) | 1 (4) | 1 (25) | 0.086 |
| Ataxia; n (%) | 28 (88) | 22 (85) | 4 (100) | 1 |
| Areflexia; n (%) | 29 (91) | 26 (100) | 4 (100) | 0.384 |
| Cranial nerve deficits; n (%) | ||||
| VII | 9 (28) | 3 (12) | 0 (0) | 0.209 |
| IX, X | 7 (22) | 2 (8) | 2 (50) | 0.057 |
| Sensory disturbances; n (%) | 26 (81) | 7 (27) | 4 (100) | <0.0001* |
| Superficial | 23 (72) | 7 (27) | 4 (100) | 0.0003† |
| Deep | 10 (31) | 1 (4) | 1 (25) | 0.020‡ |
*Group 2 vs Group 1, odds ratio (OR) 0.085 (95% confidence intervals (CI) 0.025 to 0.294); Group 2 vs Group 3, p = 0.012.
†Group 2 vs Group 1, OR 0.144 (95% CI 0.045 to 0.460); Group 2 vs Group 3, p = 0.012.
‡Group 2 vs Group 1, OR 0.088 (95% CI 0.010 to 0.743); Group 2 vs Group 3, OR 0.120 (95% CI 0.006 to 2.458).
MFS; Miller Fisher syndrome.